This alarming statistic highlights the pressing need for increased road safety awareness
uae14 hours ago
M42, an Abu Dhabi-headquartered tech-enabled health company, and AstraZeneca, a global leader in science-led biopharmaceuticals, inked an agreement to advance preventive cancer care and next-generation precision medicine.
As AstraZeneca’s clinical genomics partner of choice in the region, M42 will conduct sequencing of hereditary breast cancer genes, to develop personalised care and prevention strategies tailored to the specific needs of each patient.
Breast cancer is the most common cancer among women worldwide. According to the Ministry of Health and Prevention (MoHAP), it is the leading cause of cancer death, resulting in 11.6 per cent of all cancer fatalities every year in the UAE.
Stay up to date with the latest news. Follow KT on WhatsApp Channels.
By facilitating the sequencing of cancer genes, M42 will facilitate in determining each patient’s genetic risk for cancer, thus ensuring that preventive measures can be explored in the early stages or even before the cancer develops. The partnership is providing one of the first companion diagnostics programmes in the Gulf, with findings that could be utilised to optimise personalised drug-based interventions for patients. The programme aims to enable preventive cancer care among all patients in UAE, Kuwait, Oman, Bahrain and Qatar.
“This pioneering programme, powered by disruptive omics technologies, aims to enable personalised cancer treatment and intervention, contributing directly to patient outcomes and paving the way for preventive medicine, in keeping with our mission to support people, not just patients, and prevention, not just treatment,” Dr Fahed Al Marzooqi, deputy group chief operating officer at M42, said.
Peter Raouf, GCC oncology business unit director at AstraZeneca, said the collaboration is a significant step forward in advancing personalised precision medicine in cancer research.
“At AstraZeneca, we are happy to be pioneering efforts in preventative cancer care by utilising M42’s state-of-the-art genomics expertise. It is our priority to continue striving to enhance patient outcomes for the health of people, society, and the planet.”
The sequencing will be carried out at M42’s Omics Centre of Excellence, one of the largest multi-omics research facilities in the world with a specific focus on generating advanced genomics knowledge. The centre has been instrumental in facilitating one of the largest population genomic initiatives in the world, the Emirati Genome Programme.
For this study, research efforts will focus on patients from UAE, Kuwait, Oman, Bahrain and Qatar to strengthen genomics knowledge related to non-Western population groups, which are typically under-represented in clinical research. Under the agreement, the first hospital to collect genomics data from consenting patients will be Cleveland Clinic Abu Dhabi.
ALSO READ:
This alarming statistic highlights the pressing need for increased road safety awareness
uae14 hours ago
Some owners of the 51-storey building welcomed face-scanning access in the premises which would curb illegal subletting
uae15 hours ago
Two expats will be sharing the grand prize with family and friends who pitched in for the tickets
uae15 hours ago
He reiterated that the football club 'operates on the principle of transparency'
uae16 hours ago
Nearly 5,000 pilgrims have benefited from the 'Tayseer Umrah' initiative in the last five years
uae17 hours ago
The young author's journey began at six when he discovered the joy of reading while memorising the Quran
uae18 hours ago
Using platforms like Instagram, TikTok, and YouTube, these writers share their stories and ideas in a way that speaks to today's youth
uae23 hours ago
'The food I make is more than just ingredients. It’s filled with love and care,' said the owner of a home-based bakery
uae1 day ago